Nature Communications 2024 14 August . Trial results were recently shared in a study published in nature communications. The editor in chief is lesley anson.
    
 
         
     
 
     
 
Multidisciplinary, open access journal, with 14.7 impact factor, 8 days to first decision and 114m annual downloads. This proved popular, with over 45% of authors choosing to.
 
Nature Communications 2024 14 August Images References : 
         
        Source: mufibrosabelle.pages.dev  
Nature Communications Impact Factor 2024 Kaela Maridel , “observation of quantum thermalization restricted to hilbert space fragments,” march 14, 2024.
 
         
        Source: jackywillyt.pages.dev  
Nature Communications If 2024 Jojo Roslyn , Multidisciplinary, open access journal, with 14.7 impact factor, 8 days to first decision and 114m annual downloads.
 
         
        Source: meggiqalbertine.pages.dev  
Nature Communications Impact Factor 2024 Eilis Harlene , Browse all the issues in volume 14 of nature communications
 
         
        Source: www.sohu.com  
【期刊解析】浅析Nature Communications搜狐大视野搜狐新闻 , Article open access 29 nov 2024 ultrafast adaptive optics for imaging the living human eye adaptive optics (ao) corrects eye aberrations for sharp imaging, but their.
 
         
        Source: blogs.taz.de  
Hier spricht der Aushilfshausmeister! » Aus der Natur rauskommen/Die , “observation of quantum thermalization restricted to hilbert space fragments,” march 14, 2024.
 
         
        Source: blog.sciencenet.cn  
科学网—王国燕团队CNS封面设计作品案例(7):潘建伟院士量子通讯Nature 王国燕的博文 , Trial results were recently shared in a study published in nature communications.
 
         
        Source: jaspershen.github.io  
Nature Communications Xiaotao Shen , The editor in chief is lesley anson.
 
         
        Source: blog.sciencenet.cn  
科学网—解锁Nature Communications 2022年最受欢迎的那些研究 Top 25 SpringerNature科研服务的博文 , Browse all the issues in volume 14 of nature communications
 
         
        Source: www.360zhyx.com  
45张Nature子刊封面,展现科学中的艺术杂谈转化医学网转化医学核心门户 , The phase ii clinical trial, neoactivate, enrolled patients with stage 3 melanoma;
 
         
        Source: hematologiegroningen.nl  
Nature Communications publication Hematologie Groningen , Zhao, luheng, prithvi raj datla, weikun tian, mohammad mujahid aliyu, and huanqian loh.